Our Story
ProGenis Pharmaceuticals is a leading RNA biotechnology company, founded in Perth, Western Australia, in 2022. We are dedicated to developing next-generation, precision RNA medicines for the treatment of acquired and inherited rare diseases.
Co-founded by renowned experts Professor Marvin Caruthers and Professor Rakesh Veedu, our team is driven by a shared commitment to improving the health and wellbeing of individuals through groundbreaking therapeutics.
We are driven by innovation
We are dedicated to developing breakthrough, disease-modifying therapeutics that are safer, more effective, and accessible, offering new hope to patients suffering from chronic and debilitating conditions.
Safe
No or low off-target toxicity
Effective
Precisely targeting the gene hallmark
Accessible
Affordable costs for all patients
Leadership Team
Our leadership team, board of directors and scientific advisors are seasoned experts in biotechnology, medicine, and business, providing strategic leadership to drive ProGenis Pharmaceuticals’ mission of developing innovative RNA therapeutics.
Prof. Rakesh N. Veedu
Co-Founder & Managing Director
Prof. Marvin Caruthers
Co-Founder & Director of Platform
Dr Vinod Vathipadiekal
Chief Scientific Officer
Prof. Bu Yeap
Clinical Lead
Dr Digi Kuriakose
Discovery Research Lead
Dr Haigang Cui
Pre-clinical Lead
Dr Xuena Lin
Senior Director of Development
Dr Chris Oswald
CMC Consultant & Regulatory
Board of Directors
Prof. Marvin Caruthers
Director Board Member
Prof. Rakesh N. Veedu
Director Board Member
David Schwartz
Director Board Member
Scientific Advisors
Prof. Girish Dwivedi
Clinical Advisor
Dr Snehal Shah
Paediatric Neurologist
Prof. Alan Kermode
Neurologist
Join our team!
Be part of a team committed to transforming RNA therapeutics and advancing treatments for rare diseases. We’re looking for passionate individuals to make a real impact.
